![Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study | Blood Cancer Journal Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-020-0333-2/MediaObjects/41408_2020_333_Fig1_HTML.png)
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study | Blood Cancer Journal
![FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells | Leukemia FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsj.leu.2404510/MediaObjects/41375_2007_Article_BF2404510_Fig2_HTML.jpg)
FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells | Leukemia
![Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia | NEJM Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1994/nejm_1994.330.issue-12/nejm199403243301204/production/images/img_medium/nejm199403243301204_t1.jpeg)
Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia | NEJM
Ravendex on Twitter: "@cardano_daily @adax_pro @wmtoken @get_revuto @kicklaunchpad @CamelcoinThe @peepsule @Pavia_io @ArdanaProject Ravendex Testnet Coming On @Milkomeda_com Soon!" / Twitter
![Frontiers | Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy Frontiers | Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy](https://www.frontiersin.org/files/Articles/638689/fonc-11-638689-HTML-r1/image_m/fonc-11-638689-g001.jpg)
Frontiers | Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy
![PDF) Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib than e14a2 patients PDF) Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib than e14a2 patients](https://i1.rgstatic.net/publication/26773135_Chronic_myeloid_leukemia_patients_with_the_e13a2_BCR-ABL_fusion_transcript_have_inferior_responses_to_imatinib_than_e14a2_patients/links/0fcfd507e7f06b1adb000000/largepreview.png)
PDF) Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib than e14a2 patients
![Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia | NEJM Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1994/nejm_1994.330.issue-12/nejm199403243301204/production/images/img_medium/nejm199403243301204_f1.jpeg)
Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia | NEJM
![PDF) Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart PDF) Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart](https://i1.rgstatic.net/publication/331911828_Arterial_occlusive_events_in_chronic_myeloid_leukemia_patients_treated_with_ponatinib_in_the_real-life_practice_are_predicted_by_the_Systematic_Coronary_Risk_Evaluation_SCORE_chart/links/5cf3352c4585153c3dab7141/largepreview.png)
PDF) Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
![An NMR Study of the Bortezomib Degradation under Clinical Use Conditions – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub. An NMR Study of the Bortezomib Degradation under Clinical Use Conditions – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.](https://cyberleninka.org/viewer_images/1193886/f/1.png)
An NMR Study of the Bortezomib Degradation under Clinical Use Conditions – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.
![COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report - Breccia - 2022 - British Journal of Haematology - Wiley Online Library COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report - Breccia - 2022 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/e7828996-fe4c-467c-b0b1-0b1d43ba1f23/bjh17890-fig-0001-m.png)